JW Pharmaceutical Corporation (001065.KS)
KRW 29450.0
(-1.01%)
KRW 29450.0
(-1.01%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 37 Billion KRW | 16.04% |
| 2022 | 31.89 Billion KRW | 2312.47% |
| 2021 | -1.44 Billion KRW | 90.56% |
| 2020 | -15.27 Billion KRW | 39.56% |
| 2019 | -25.27 Billion KRW | -413.71% |
| 2018 | 8.05 Billion KRW | 1185.14% |
| 2017 | -742.47 Million KRW | 93.21% |
| 2016 | -10.93 Billion KRW | -657.43% |
| 2015 | 1.96 Billion KRW | 35.56% |
| 2014 | 1.44 Billion KRW | -36.4% |
| 2013 | 2.27 Billion KRW | 111.15% |
| 2012 | -20.39 Billion KRW | -108.02% |
| 2011 | -9.8 Billion KRW | -275.06% |
| 2010 | 5.6 Billion KRW | -48.71% |
| 2009 | 10.91 Billion KRW | 69.73% |
| 2008 | 6.43 Billion KRW | -26.57% |
| 2007 | 8.76 Billion KRW | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | 20.08 Billion KRW | -19.54% |
| 2024 Q2 | 8.51 Billion KRW | -57.63% |
| 2023 Q3 | -17.91 Billion KRW | -224.15% |
| 2023 Q2 | 14.42 Billion KRW | -7.08% |
| 2023 Q1 | 15.52 Billion KRW | 19.12% |
| 2023 FY | 37 Billion KRW | 16.04% |
| 2023 Q4 | 24.96 Billion KRW | 239.38% |
| 2022 Q4 | 13.03 Billion KRW | 57.21% |
| 2022 FY | 31.89 Billion KRW | 2312.47% |
| 2022 Q1 | 9.58 Billion KRW | 242.48% |
| 2022 Q2 | 982.23 Million KRW | -89.75% |
| 2022 Q3 | 8.29 Billion KRW | 744.09% |
| 2021 Q1 | 4.03 Billion KRW | 158.02% |
| 2021 Q2 | -3.36 Billion KRW | -183.42% |
| 2021 Q3 | 5.09 Billion KRW | 251.33% |
| 2021 FY | -1.44 Billion KRW | 90.56% |
| 2021 Q4 | -6.72 Billion KRW | -232.14% |
| 2020 Q4 | -6.94 Billion KRW | -335.45% |
| 2020 Q1 | -2.73 Billion KRW | 88.2% |
| 2020 FY | -15.27 Billion KRW | 39.56% |
| 2020 Q3 | 2.95 Billion KRW | 134.71% |
| 2020 Q2 | -8.5 Billion KRW | -210.38% |
| 2019 Q1 | -4.67 Billion KRW | 36.63% |
| 2019 FY | -25.27 Billion KRW | -413.71% |
| 2019 Q2 | 1.47 Billion KRW | 131.57% |
| 2019 Q4 | -23.21 Billion KRW | -2131.97% |
| 2019 Q3 | 1.14 Billion KRW | -22.57% |
| 2018 Q4 | -7.37 Billion KRW | -420.03% |
| 2018 Q3 | 2.3 Billion KRW | -72.93% |
| 2018 Q2 | 8.51 Billion KRW | 84.51% |
| 2018 Q1 | 4.61 Billion KRW | 173.01% |
| 2018 FY | 8.05 Billion KRW | 1185.14% |
| 2017 Q4 | -6.32 Billion KRW | -209.76% |
| 2017 Q3 | 5.75 Billion KRW | 641.47% |
| 2017 Q2 | -1.06 Billion KRW | -220.46% |
| 2017 Q1 | 882.82 Million KRW | -89.79% |
| 2017 FY | -742.47 Million KRW | 93.21% |
| 2016 Q3 | -4.76 Billion KRW | 70.62% |
| 2016 Q2 | -16.23 Billion KRW | -1242.39% |
| 2016 Q1 | 1.42 Billion KRW | 81.45% |
| 2016 FY | -10.93 Billion KRW | -657.43% |
| 2016 Q4 | 8.64 Billion KRW | 281.31% |
| 2015 Q1 | 482.19 Million KRW | -88.52% |
| 2015 Q4 | 783.05 Million KRW | -27.27% |
| 2015 Q3 | 1.07 Billion KRW | 382.97% |
| 2015 Q2 | -380.49 Million KRW | -178.91% |
| 2015 FY | 1.96 Billion KRW | 35.56% |
| 2014 FY | 1.44 Billion KRW | -36.4% |
| 2014 Q4 | 4.19 Billion KRW | 642.23% |
| 2014 Q3 | 565.84 Million KRW | 111.73% |
| 2014 Q2 | -4.82 Billion KRW | -420.76% |
| 2014 Q1 | 1.5 Billion KRW | 1379.93% |
| 2013 Q4 | 101.58 Million KRW | -82.14% |
| 2013 FY | 2.27 Billion KRW | 111.15% |
| 2013 Q1 | 683 Million KRW | 107.81% |
| 2013 Q2 | 921.47 Million KRW | 34.92% |
| 2013 Q3 | 568.81 Million KRW | -38.27% |
| 2012 Q4 | -8.74 Billion KRW | -341.54% |
| 2012 FY | -20.39 Billion KRW | -108.02% |
| 2012 Q3 | -1.98 Billion KRW | 79.18% |
| 2012 Q1 | 245.46 Million KRW | 0.0% |
| 2012 Q2 | -9.51 Billion KRW | -3976.7% |
| 2011 Q4 | - KRW | 100.0% |
| 2011 Q2 | 602.59 Million KRW | -56.57% |
| 2011 Q1 | 1.38 Billion KRW | 173.62% |
| 2011 Q3 | -3.92 Billion KRW | -750.55% |
| 2011 FY | -9.8 Billion KRW | -275.06% |
| 2010 Q4 | -1.88 Billion KRW | -336.62% |
| 2010 FY | 5.6 Billion KRW | -48.71% |
| 2010 Q1 | 5.31 Billion KRW | 70.8% |
| 2010 Q3 | 796.54 Million KRW | -41.88% |
| 2010 Q2 | 1.37 Billion KRW | -74.23% |
| 2009 Q2 | 3.56 Billion KRW | -30.39% |
| 2009 Q4 | 3.11 Billion KRW | 448.77% |
| 2009 Q3 | -892.72 Million KRW | -125.01% |
| 2009 Q1 | 5.12 Billion KRW | 312.61% |
| 2009 FY | 10.91 Billion KRW | 69.73% |
| 2008 Q2 | 4.38 Billion KRW | 0.38% |
| 2008 Q3 | 110.76 Million KRW | -97.47% |
| 2008 FY | 6.43 Billion KRW | -26.57% |
| 2008 Q4 | -2.41 Billion KRW | -2277.72% |
| 2008 Q1 | 4.36 Billion KRW | 215.49% |
| 2007 Q4 | -3.78 Billion KRW | -235.76% |
| 2007 Q1 | 4.65 Billion KRW | 0.0% |
| 2007 Q2 | 5.1 Billion KRW | 9.71% |
| 2007 FY | 8.76 Billion KRW | 0.0% |
| 2007 Q3 | 2.78 Billion KRW | -45.42% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 615.344% |
| Dong-A Socio Holdings Co., Ltd. | 57.98 Billion KRW | 36.184% |
| Ildong Holdings Co., Ltd. | -59.58 Billion KRW | 162.105% |
| HANDOK Inc. | -28.79 Billion KRW | 228.506% |
| Kukje Pharma Co., Ltd. | -8.41 Billion KRW | 539.757% |
| Yuhan Corporation | 93.5 Billion KRW | 60.425% |
| Dong-A ST Co., Ltd. | 11.12 Billion KRW | -232.717% |
| SAMSUNG PHARM. Co., LTD. | -24.81 Billion KRW | 249.147% |
| Hanmi Pharm. Co., Ltd. | 146.23 Billion KRW | 74.693% |
| Hanall Biopharma Co.,Ltd | 3.5 Billion KRW | -954.73% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1576.465% |
| Dong Sung Bio Pharm.Co.,Ltd. | -2.07 Billion KRW | 1884.376% |
| MYUNGMOON Pharm co.,Ltd | -4.52 Billion KRW | 917.849% |
| Hana Pharm Co., Ltd. | 22.33 Billion KRW | -65.704% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 615.344% |
| Ilsung Pharmaceuticals Co., Ltd. | -20.94 Billion KRW | 276.718% |
| REYON Pharmaceutical Co., Ltd. | 3.58 Billion KRW | -932.723% |
| Aprogen pharmaceuticals,Inc. | -118.26 Billion KRW | 131.29% |
| JW Holdings Corporation | 19.02 Billion KRW | -94.501% |
| Ildong Pharmaceutical Co., Ltd. | -78.92 Billion KRW | 146.886% |
| Chong Kun Dang Pharmaceutical Corp. | 212.52 Billion KRW | 82.587% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 164.555% |
| Hyundai Pharmaceutical Co., Ltd. | 6.12 Billion KRW | -504.505% |
| Samil Pharmaceutical Co.,Ltd | 1.66 Billion KRW | -2124.554% |
| Jeil Pharmaceutical Co.,Ltd | 5 Billion KRW | -639.425% |
| Yuyu Pharma, Inc. | -7.18 Billion KRW | 615.344% |
| Kwang Dong Pharmaceutical Co., Ltd. | 36.96 Billion KRW | -0.11% |
| Daewoong pharmaceutical Co.,Ltd | 111.5 Billion KRW | 66.811% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 0.0% |
| Yuhan Corporation | 93.5 Billion KRW | 60.425% |
| Jeil Pharma Holdings Inc | -16.24 Billion KRW | 327.735% |
| Yungjin Pharm. Co., Ltd. | -3.87 Billion KRW | 1054.868% |
| Suheung Co., Ltd. | 6.11 Billion KRW | -504.755% |
| JW Pharmaceutical Corporation | 37 Billion KRW | 0.0% |
| Samjin Pharmaceuticals Co., Ltd. | 18.9 Billion KRW | -95.741% |
| Korea United Pharm Inc. | 48.26 Billion KRW | 23.322% |
| CKD Bio Corp. | -24.19 Billion KRW | 252.966% |
| Daewon Pharmaceutical Co., Ltd. | 23.91 Billion KRW | -54.729% |
| Dongwha Pharm.Co.,Ltd | 27.43 Billion KRW | -34.871% |
| Whan In Pharm Co.,Ltd. | 29.77 Billion KRW | -24.289% |
| Shin Poong Pharm.Co.,Ltd. | -57.32 Billion KRW | 164.555% |
| Chong Kun Dang Holdings Corp. | 47 Billion KRW | 21.276% |
| Boryung Corporation | 40.2 Billion KRW | 7.951% |
| Bukwang Pharmaceutical Co., Ltd. | -31.32 Billion KRW | 218.119% |
| Ilyang Pharmaceutical Co.,Ltd | -2.5 Billion KRW | 1576.465% |
| JW Lifescience Corporation | 28.14 Billion KRW | -31.489% |